Comparative Pharmacology
Head-to-head clinical analysis: PEDIAMYCIN 400 versus ZITHROMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PEDIAMYCIN 400 versus ZITHROMAX.
PEDIAMYCIN 400 vs ZITHROMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin binds to the 50S subunit of the bacterial ribosome and inhibits protein synthesis by blocking the translocation step.
Azithromycin is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by preventing translocation of peptides. It also has immunomodulatory and anti-inflammatory effects.
400 mg orally every 6 hours for 10 days.
500 mg orally once daily for 3 days, or 2 g orally as a single dose for certain infections.
None Documented
None Documented
1.5-2 hours; prolonged in renal impairment (up to 6 hours)
Terminal elimination half-life of approximately 68 hours (range 35-96 hours), allowing once-weekly dosing for some indications.
Renal (80-90% unchanged); biliary/fecal (minor, <5%)
Primarily eliminated via biliary/fecal route (∼50-60% as unchanged drug); renal excretion accounts for ∼12% of the dose; minimal metabolism.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic